Drug Trial Radar · NCT06672172
A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
284
Actual
Start
Sep 25, 2024
Primary completion
Nov 13, 2025
Study completion Apr 17, 2026
Sponsor
- Lead sponsor
- Shandong Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to evaluate the efficacy and safety of HRS-7535 compared with placebo in subjects with type 2 diabetes mellitus with inadequate glycemic control with diet and exercise
Conditions
- Type 2 Diabetes
Interventions
HRS-7535 tabletDrug
HRS-7535 tablet; low dose
HRS-7535 tabletDrug
HRS-7535 tablet; middle dose
HRS-7535 tabletDrug
HRS-7535 tablet; high dose
HRS-7535 placebo tabletDrug
HRS-7535 placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in HbA1c at 32 weeks of treatmentTime frame: at 32 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.